← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #93 OF 1,000 MOST-CITED

Management review - Lack of or inadequate procedures

FDA cited this observation 302 times across 286 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices302
BY FISCAL YEAR
FY202611
FY202542
FY202425
FY202329
FY202223
FY202110
FY202020
FY201940
FY201826
FY201736
FY201640

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.6× the rate of the average FDA-cited firm (12.6% vs 7.7%), across 286 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Procedures for management review have not been established.

BAND CONNECT · Cincinnati, Ohio · Devices · 2025-12-12

Procedures for management review have not been adequately established.

Mid Central Medical, LLC. · Saint Vincent, Minnesota · Devices · 2025-12-09

Procedures for management review have not been established.

ASEPTIKITS, LLC · North Salt Lake, Utah · Devices · 2025-12-03

Procedures for management review have not been adequately established.

OnePacs, LLC · Machesney Park, Illinois · Devices · 2025-12-02

Procedures for management review have not been adequately established.

Kerber USA Inc. · Amherst, New York · Devices · 2025-11-07

Procedures for management review have not been established.

R.G. Enterprises (U.S.A.) Inc. · Madison Heights, Michigan · Devices · 2025-11-05

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →